These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11745189)

  • 21. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
    Naski MC; Wang Q; Xu J; Ornitz DM
    Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated H-ras gene mutations in transitional cell carcinoma of urinary bladder in a Kashmiri population.
    Pandith AA; Shah Z; Rasool R; Dil-Afroze ; Yousuf A; Parveen N; Wani S; Siddiqi M
    Tumori; 2010; 96(6):993-8. PubMed ID: 21388064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data.
    Tsai FJ; Tsai CH; Chang JG; Wu JY
    Am J Med Genet; 1999 Sep; 86(3):300-1. PubMed ID: 10482885
    [No Abstract]   [Full Text] [Related]  

  • 24. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1).
    Rousseau F; el Ghouzzi V; Delezoide AL; Legeai-Mallet L; Le Merrer M; Munnich A; Bonaventure J
    Hum Mol Genet; 1996 Apr; 5(4):509-12. PubMed ID: 8845844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiological and histological variants of thanatophoric dysplasia are associated with common mutations in FGFR-3.
    Nerlich AG; Freisinger P; Bonaventure J
    Am J Med Genet; 1996 May; 63(1):155-60. PubMed ID: 8723102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.
    Logié A; Dunois-Lardé C; Rosty C; Levrel O; Blanche M; Ribeiro A; Gasc JM; Jorcano J; Werner S; Sastre-Garau X; Thiery JP; Radvanyi F
    Hum Mol Genet; 2005 May; 14(9):1153-60. PubMed ID: 15772091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stop codon FGFR3 mutations in thanatophoric dwarfism type 1.
    Rousseau F; Saugier P; Le Merrer M; Munnich A; Delezoide AL; Maroteaux P; Bonaventure J; Narcy F; Sanak M
    Nat Genet; 1995 May; 10(1):11-2. PubMed ID: 7647778
    [No Abstract]   [Full Text] [Related]  

  • 28. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
    Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
    Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations of fibroblast growth factor receptor 3 gene (FGFR3) in transitional cell carcinoma of urinary bladder in Thai patients [Revision-2a].
    Jantip J; Tanthanuch M; Kanngurn S; Karnchanawanichkul W; Pripatnanont C; Sangkhathat S; Thongsuksai P
    J Med Assoc Thai; 2013 Aug; 96(8):976-83. PubMed ID: 23991606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia.
    Wilcox WR; Tavormina PL; Krakow D; Kitoh H; Lachman RS; Wasmuth JJ; Thompson LM; Rimoin DL
    Am J Med Genet; 1998 Jul; 78(3):274-81. PubMed ID: 9677066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer.
    Pandith AA; Hussain A; Khan MS; Shah ZA; Wani MS; Siddiqi MA
    Asian Pac J Cancer Prev; 2016; 17(6):2787-93. PubMed ID: 27356691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident.
    Yamamoto S; Romanenko A; Wei M; Masuda C; Zaparin W; Vinnichenko W; Vozianov A; Lee CC; Morimura K; Wanibuchi H; Tada M; Fukushima S
    Cancer Res; 1999 Aug; 59(15):3606-9. PubMed ID: 10446970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of RAS family genes in urothelial carcinoma.
    Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
    J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 Gene mutations in superficial bladder cancer.
    Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
    Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term survival in typical thanatophoric dysplasia type 1.
    Baker KM; Olson DS; Harding CO; Pauli RM
    Am J Med Genet; 1997 Jun; 70(4):427-36. PubMed ID: 9182787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
    Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Amorós A; Tardón A; Carrato A; Serra C; Malats N; Real FX
    J Clin Oncol; 2006 Aug; 24(22):3664-71. PubMed ID: 16877735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The study of p53 gene mutation in human bladder cancer].
    Ding Q; Zhang Y; Sun X
    Zhonghua Wai Ke Za Zhi; 1995 Nov; 33(11):684-6. PubMed ID: 8731915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations.
    Karlou M; Saetta AA; Korkolopoulou P; Levidou G; Papanastasiou P; Boltetsou E; Isaiadis D; Pavlopoulos P; Thymara I; Thomas-Tsagli E; Patsouris E
    Pathology; 2009; 41(4):327-34. PubMed ID: 19404844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions.
    Matsumoto M; Ohtsuki Y; Ochii K; Seike Y; Iseda N; Sasaki T; Okada Y; Kurabayashi A; Furihata M
    Oncol Rep; 2004 Nov; 12(5):967-71. PubMed ID: 15492779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.